found semaglutide reduced the risk of major adverse CV events vs placebo in people with type 2 diabetes and atherosclerotic CV disease and/or chronic kidney disease (3.1 vs 3.7 events per 100 person-years, respectively; HR 0.86; 95% CI 0.77 to 0.96; P=0.006)
was a double-blind, placebo-controlled, event-driven, superiority trial
randomly assigned participants who were 50 years of age or older, had type 2 diabetes with a glycated hemoglobin level of 6.5 to 10.0%, and had known atherosclerotic cardiovascular disease, chronic kidney disease, or both to receive either once-daily oral semaglutide (maximal dose, 14 mg) or placebo, in addition to standard care
primary outcome was major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke), assessed in a time-to-first-event analysis
Reference:
McGuire DK et al; for the SOUL Study Group. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. NJEM March 29, 2025
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.